NCT06337643View on ClinicalTrials.gov

A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

March 7, 2023

Primary Completion Date

April 16, 2024

Study Completion Date

April 16, 2024

Conditions
Pneumococcal Vaccine
Interventions
BIOLOGICAL

MVX01

Pneumococcal Vaccine Candidate

BIOLOGICAL

MVX01 Placebo

Placebo

Trial Locations (2)

31406

Velocity (Meridian) Clinical Research, Savannah

37909

Alliance for Multispecialty Research (AMR), Knoxville

Sponsors
All Listed Sponsors
lead

Matrivax Research and Development Corporation

INDUSTRY